The FDA has granted Fast Track designation to ASP1128, an investigational treatment for patients at increased risk of developing moderate to severe AKI after CABG and/or valve surgery.
Researchers created a personalized risk prediction tools that can estimate long-term MACE and angina outcomes after revascularization in patients with diabetes and multivessel disease.
In Denmark, investigators conducted twin studies determining no association between genetics and early environment with depression and ischemic heart disease.
Five-year rates of a composite outcome of death, stroke, and myocardial infarction are similar for patients with left main coronary artery disease following either percutaneous coronary intervention or coronary artery bypass grafting.
Intravascular lithotripsy was safe, with no reported major dissections, perforations, abrupt closure, or slow flow/no reflow in patients with complex coronary lesions.
Serum uric acid level was an independent predictor of non-calcified plaques on coronary computed tomography angiography in asymptomatic individuals after adjusting for cardiovascular risk factors.
Investigators sought to determine whether percutaneous coronary intervention with drug-coated balloons is a better treatment option for coronary artery lesions than percutaneous coronary intervention with bare-metal stents.
Researchers used coronary computed tomography angiography to determine whether the rate of coronary plaque progression is different in people with vs without diabetes.
In a study, coronary revascularization was associated with improved survival in high-risk but not low-risk patients with chronic kidney disease patients on Medicare.
